Entered into a Phase 1 clinical study for the treatment of patients with selected advanced solid tumors in July 2018.

Tumor infiltrating lymphocytes express multiple immune checkpoints and co-stimulatory receptors. Xencor’s bispecific tumor microenvironment (TME) activators seek to more effectively reactivate these tumor-killing T cells by engaging multiple T-cell targets simultaneously. This approach eliminates the need for the multiple antibodies, and it allows for more selective targeting of T cells with high checkpoint expression, which may potentially improve the therapeutic index of combination immunotherapies.

XmAb717 (XmAb20717) is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. Xencor’s XmAb® bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture. XmAb bispecific Fc domains have been engineered to eliminate Fc gamma receptor (FcγR) binding, with the intent to prevent activation and/or depletion of T cells via engagement by FcγR-expressing cells. In preclinical studies, dual blockade of PD-1 and CTLA-4 with XmAb717 significantly enhanced T cell proliferation and activation, and anti-tumor activity in vivo.

Each of Xencor’s three bispecific TME activators tests a distinct mechanism of TME activation. XmAb841 and XmAb104 are also being evaluated in Phase 1 clinical studies.